ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
ImmunoGen anticipates using the net proceeds of the offering, together with its existing capital, to fund its operations, including, but not limited to, research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.
Jefferies,
The securities described above were offered by ImmunoGen pursuant to a
shelf registration statement that was previously filed with and declared
effective by the
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary antibody-drug
conjugate (ADC) technology. The Company's lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in
combination regimens for earlier-stage disease. ImmunoGen has three
additional clinical-stage compounds, two of which are being developed in
collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is
also used in Roche's marketed product, Kadcyla® and in
programs in development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
This press release includes forward-looking statements, including
statements related to the public offering of securities by ImmunoGen,
including statements about the anticipated use of the net proceeds of
the offering. For these statements, ImmunoGen claims the protection of
the safe harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. Various factors could
cause actual results to differ materially from those discussed or
implied in the forward-looking statements, and you are cautioned not to
place undue reliance on these forward-looking statements, which are
current only as of the date of this release. Factors that could cause
future results to differ materially from such expectations include, but
are not limited to: uncertainties inherent in the initiation of future
clinical trials and such other factors more fully described in
ImmunoGen's transition report on Form 10-K for the six-month period
ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20171011006029/en/
For Investors
sarah.kiely@immunogen.com
or
For
Media
Courtney O'Konek, 781-895-0158
courtney.okonek@immunogen.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media